Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. on December 18, 2017. The registrant is a Delaware corporation focused on developing therapeutic proteins. The report addresses a specific regulatory milestone regarding its clinical development program.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary event reported is a regulatory approval from the Korean Ministry of Food and Drug Safety (MFDS). The MFDS approved a protocol amendment for the ongoing Phase 1/2 multi-dose study of the company's subcutaneously administered, prophylactic Factor IX variant, CB 2679d/ISU304. The amendment allows the study to omit single-dose Cohort 4 and proceed directly to multi-dose Cohort 5 daily.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the study acceleration. The filing does not provide updated financial guidance, long-term outlook, or specific risk factors beyond the inherent uncertainties of clinical trials. The acceleration of the study protocol is presented as a positive development for the development timeline of CB 2679d/ISU304.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed study parameters.
- Confirm the status of the Phase 1/2 study in other jurisdictions (e.g., FDA) to assess global development alignment.
- Review subsequent filings for enrollment updates or safety data from the accelerated Cohort 5.
- Check the company's cash runway in the most recent 10-Q or 10-K, as this filing contains no liquidity data.